Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Causes of thrombocytopenia in children

Donald L Yee, MD
Section Editors
Donald H Mahoney, Jr, MD
Lawrence LK Leung, MD
Deputy Editor
Carrie Armsby, MD, MPH


Thrombocytopenia is defined as a platelet count of <150,000/microL. It is clinically suspected when there is a history of easy bruising or bleeding, or it may present as an incidental finding during routine evaluation or during investigations performed for other reasons.

Causes of thrombocytopenia in children will be reviewed here. Causes of neonatal thrombocytopenia in neonates differ somewhat and are reviewed separately. (See "Causes of neonatal thrombocytopenia".)

The approach to evaluating a child with unexplained thrombocytopenia and/or bleeding symptoms and the details of specific causes of thrombocytopenia (eg, immune thrombocytopenia, leukemia, aplastic anemia) are discussed in separate topic reviews:

(See "Approach to the child with unexplained thrombocytopenia".)

(See "Approach to the child with bleeding symptoms".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Nov 10, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004; 103:390.
  2. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113:2386.
  3. Price V. Auto-immune lymphoproliferative disorder and other secondary immune thrombocytopenias in childhood. Pediatr Blood Cancer 2013; 60 Suppl 1:S12.
  4. Liebman H. Other immune thrombocytopenias. Semin Hematol 2007; 44:S24.
  5. Avila ML, Shah V, Brandão LR. Systematic review on heparin-induced thrombocytopenia in children: a call to action. J Thromb Haemost 2013; 11:660.
  6. Takemoto CM, Streiff MB. Heparin-induced thrombocytopenia screening and management in pediatric patients. Hematology Am Soc Hematol Educ Program 2011; 2011:162.
  7. Gesundheit B, Kirby M, Lau W, et al. Thrombocytopenia and megakaryocyte dysplasia: an adverse effect of valproic acid treatment. J Pediatr Hematol Oncol 2002; 24:589.
  8. Proulle V, Masnou P, Cartron J, et al. GPIaIIa as a candidate target for anti-platelet autoantibody occurring during valproate therapy and associated with peroperative bleeding. Thromb Haemost 2000; 83:175.
  9. http://www.ouhsc.edu/platelets/ditp.html (Accessed on October 30, 2017).
  10. Pérez-Rodríguez A, Lourés E, Rodríguez-Trillo Á, et al. Inherited ADAMTS13 deficiency (Upshaw-Schulman syndrome): a short review. Thromb Res 2014; 134:1171.
  11. Greinacher A, Selleng K. Thrombocytopenia in the intensive care unit patient. Hematology Am Soc Hematol Educ Program 2010; 2010:135.
  12. Thiele T, Selleng K, Selleng S, et al. Thrombocytopenia in the intensive care unit-diagnostic approach and management. Semin Hematol 2013; 50:239.
  13. Bick RL. Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits. Semin Thromb Hemost 1985; 11:249.
  14. Corrigan JJ Jr. Thrombocytopenia: a laboratory sign of septicemia in infants and children. J Pediatr 1974; 85:219.
  15. Hashimoto H, Maruyama H, Fujimoto K, et al. Hematologic findings associated with thrombocytopenia during the acute phase of exanthem subitum confirmed by primary human herpesvirus-6 infection. J Pediatr Hematol Oncol 2002; 24:211.
  16. La Russa VF, Innis BL. Mechanisms of dengue virus-induced bone marrow suppression. Baillieres Clin Haematol 1995; 8:249.
  17. Sarode R, Garewal G, Marwaha N, et al. Pancytopenia in nutritional megaloblastic anaemia. A study from north-west India. Trop Geogr Med 1989; 41:331.
  18. Perlman MK, Schwab JG, Nachman JB, Rubin CM. Thrombocytopenia in children with severe iron deficiency. J Pediatr Hematol Oncol 2002; 24:380.
  19. Kumar R, Kahr WH. Congenital thrombocytopenia: clinical manifestations, laboratory abnormalities, and molecular defects of a heterogeneous group of conditions. Hematol Oncol Clin North Am 2013; 27:465.
  20. Balduini CL, Savoia A, Seri M. Inherited thrombocytopenias frequently diagnosed in adults. J Thromb Haemost 2013; 11:1006.
  21. Melazzini F, Zaninetti C, Balduini CL. Bleeding is not the main clinical issue in many patients with inherited thrombocytopaenias. Haemophilia 2017; 23:673.
  22. Favier R, Raslova H. Progress in understanding the diagnosis and molecular genetics of macrothrombocytopenias. Br J Haematol 2015; 170:626.
  23. Noris P, Klersy C, Zecca M, et al. Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. J Thromb Haemost 2009; 7:2131.
  24. Savoia A, Balduini CL, Savino M, et al. Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard-Soulier syndrome. Blood 2001; 97:1330.
  25. Bragadottir G, Birgisdottir ER, Gudmundsdottir BR, et al. Clinical phenotype in heterozygote and biallelic Bernard-Soulier syndrome--a case control study. Am J Hematol 2015; 90:149.
  26. Van Geet C, Devriendt K, Eyskens B, et al. Velocardiofacial syndrome patients with a heterozygous chromosome 22q11 deletion have giant platelets. Pediatr Res 1998; 44:607.
  27. Seri M, Pecci A, Di Bari F, et al. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 2003; 82:203.
  28. Dong F, Li S, Pujol-Moix N, et al. Genotype-phenotype correlation in MYH9-related thrombocytopenia. Br J Haematol 2005; 130:620.
  29. Han KH, Lee H, Kang HG, et al. Renal manifestations of patients with MYH9-related disorders. Pediatr Nephrol 2011; 26:549.
  30. Pecci A, Panza E, Pujol-Moix N, et al. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat 2008; 29:409.
  31. Del Vecchio GC, Giordani L, De Santis A, De Mattia D. Dyserythropoietic anemia and thrombocytopenia due to a novel mutation in GATA-1. Acta Haematol 2005; 114:113.
  32. Yu C, Niakan KK, Matsushita M, et al. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. Blood 2002; 100:2040.
  33. Balduini CL, De Candia E, Savoia A. Why the disorder induced by GATA1 Arg216Gln mutation should be called "X-linked thrombocytopenia with thalassemia" rather than "X-linked gray platelet syndrome". Blood 2007; 110:2770.
  34. Stritt S, Nurden P, Turro E, et al. A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss. Blood 2016; 127:2903.